Elimination of Aicardi–Goutières syndrome protein SAMHD1 activates cellular innate immunity and suppresses SARS-CoV-2 replication
暂无分享,去创建一个
R. Schinazi | Baek Kim | Dong-Hyun Kim | K. Zandi | Adrian Oo | C. Shepard | L. Bassit | Katie Musall | Shu Ling Goh | Y. Cho
[1] Brenda J. Crowe,et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial , 2021, The Lancet Respiratory Medicine.
[2] T. Dörner,et al. Altered increase in STAT1 expression and phosphorylation in severe COVID‐19 , 2021, medRxiv.
[3] J. Casanova,et al. Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs , 2021, The Journal of experimental medicine.
[4] Jourdan K. Ewoldt,et al. SARS-CoV-2 Disrupts Proximal Elements in the JAK-STAT Pathway , 2021, Journal of virology.
[5] Guilin Wang,et al. Dynamic innate immune response determines susceptibility to SARS-CoV-2 infection and early replication kinetics , 2021, The Journal of experimental medicine.
[6] A. Fassati,et al. The Role of Capsid in the Early Steps of HIV-1 Infection: New Insights into the Core of the Matter , 2021, Viruses.
[7] Qian Li,et al. Baricitinib Ameliorates Experimental Autoimmune Encephalomyelitis by Modulating the Janus Kinase/Signal Transducer and Activator of Transcription Signaling Pathway , 2021, Frontiers in Immunology.
[8] S. Nisole,et al. SARS-CoV-2 Triggers an MDA-5-Dependent Interferon Response Which Is Unable To Control Replication in Lung Epithelial Cells , 2021, Journal of Virology.
[9] Sangkyu Park,et al. Differential Signaling and Virus Production in Calu-3 Cells and Vero Cells upon SARS-CoV-2 Infection , 2021, Biomolecules & therapeutics.
[10] Helio T. Navarro,et al. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia , 2020, Nature.
[11] Cameron R. Wolfe,et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 , 2020, The New England journal of medicine.
[12] S. Perlman,et al. SARS-CoV-2-induced immune activation and death of monocyte-derived human macrophages and dendritic cells. , 2020, The Journal of infectious diseases.
[13] V. Thiel,et al. Coronavirus biology and replication: implications for SARS-CoV-2 , 2020, Nature Reviews Microbiology.
[14] Brenda J. Crowe,et al. Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways , 2020, Lupus science & medicine.
[15] Vineet D. Menachery,et al. Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV , 2020, Journal of Virology.
[16] L. Ren,et al. Activation and evasion of type I interferon responses by SARS-CoV-2 , 2020, Nature Communications.
[17] F. Shan,et al. A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN-κ plus TFF2 in patients with moderate COVID-19 , 2020, EClinicalMedicine.
[18] Nicolas Carlier,et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients , 2020, Science.
[19] S. Nisole,et al. Interplay between SARS-CoV-2 and the type I interferon response , 2020, PLoS pathogens.
[20] R. Schinazi,et al. Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] F. Weber,et al. Inhibition of SARS–CoV-2 by type I and type III interferons , 2020, The Journal of Biological Chemistry.
[22] C. Scagnolari,et al. Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome–Coronavirus 2 In Vitro When Administered After Virus Infection , 2020, The Journal of Infectious Diseases.
[23] M. Fellhauer,et al. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation , 2020, Leukemia.
[24] R. Schwartz,et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.
[25] Kwok-Hung Chan,et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial , 2020, The Lancet.
[26] Benjamin J. Polacco,et al. A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing , 2020, Nature.
[27] Slobodan Paessler,et al. Antiviral activities of type I interferons to SARS-CoV-2 infection , 2020, Antiviral Research.
[28] O. Tsang,et al. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study , 2020, The Lancet Microbe.
[29] Natacha S. Ogando,et al. SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology , 2020, bioRxiv.
[30] Fabian J Theis,et al. SARS-CoV-2 Receptor ACE2 is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Enriched in Specific Cell Subsets Across Tissues , 2020, SSRN Electronic Journal.
[31] B. Koo,et al. Norovirus Replication in Human Intestinal Epithelial Cells Is Restricted by the Interferon-Induced JAK/STAT Signaling Pathway and RNA Polymerase II-Mediated Transcriptional Responses , 2020, mBio.
[32] Vineet D. Menachery,et al. Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV. , 2020, bioRxiv.
[33] M. Peppelenbosch,et al. MDA5 against enteric viruses through induction of interferon-like response partially via the JAK-STAT cascade. , 2020, Antiviral research.
[34] S. Rahman,et al. Web of interferon stimulated antiviral factors to control the influenza A viruses replication. , 2019, Microbial pathogenesis.
[35] M. Bros,et al. RhoA as a Key Regulator of Innate and Adaptive Immunity , 2019, Cells.
[36] D. Missé,et al. SAMHD1 Enhances Chikungunya and Zika Virus Replication in Human Skin Fibroblasts , 2019, International journal of molecular sciences.
[37] Fan Luo,et al. IFN-λs inhibit Hantaan virus infection through the JAK-STAT pathway and expression of Mx2 protein , 2019, Genes & Immunity.
[38] M. Santiago,et al. SAMHD1 suppresses innate immune responses to viral infections and inflammatory stimuli by inhibiting the NF-κB and interferon pathways , 2018, Proceedings of the National Academy of Sciences.
[39] D. Ivanov,et al. A SAMHD1 mutation associated with Aicardi–Goutières syndrome uncouples the ability of SAMHD1 to restrict HIV‐1 from its ability to downmodulate type I interferon in humans , 2017, Human mutation.
[40] R. Schinazi,et al. SAMHD1 controls cell cycle status, apoptosis and HIV-1 infection in monocytic THP-1 cells. , 2016, Virology.
[41] J. Rehwinkel,et al. Restriction by SAMHD1 Limits cGAS/STING-Dependent Innate and Adaptive Immune Responses to HIV-1 , 2016, Cell reports.
[42] Nan Yan,et al. RNase H2 catalytic core Aicardi-Goutières syndrome–related mutant invokes cGAS–STING innate immune-sensing pathway in mice , 2016, The Journal of experimental medicine.
[43] Yoshiya Tanaka,et al. Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study , 2016, The Journal of Rheumatology.
[44] D. Yoo,et al. Suppression of type I interferon production by porcine epidemic diarrhea virus and degradation of CREB-binding protein by nsp1 , 2016, Virology.
[45] Y. Crow,et al. Aicardi–Goutières syndrome and the type I interferonopathies , 2015, Nature Reviews Immunology.
[46] H. Takaki,et al. RIOK3-mediated phosphorylation of MDA5 interferes with its assembly and attenuates the innate immune response. , 2015, Cell reports.
[47] Robert A. Domaoal,et al. Kinetic variations between reverse transcriptases of viral protein X coding and noncoding lentiviruses , 2014, Retrovirology.
[48] Krystal L. Matthews,et al. The SARS coronavirus papain like protease can inhibit IRF3 at a post activation step that requires deubiquitination activity , 2014, Virology Journal.
[49] Mones Abu-Asab,et al. SARS-Coronavirus Open Reading Frame-9b Suppresses Innate Immunity by Targeting Mitochondria and the MAVS/TRAF3/TRAF6 Signalosome , 2014, The Journal of Immunology.
[50] R. Schinazi,et al. dNTP pool modulation dynamics by SAMHD1 protein in monocyte-derived macrophages , 2014, Retrovirology.
[51] O. Ohara,et al. Aicardi-Goutières syndrome is caused by IFIH1 mutations. , 2014, American journal of human genetics.
[52] A. Vanderver,et al. Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study , 2013, The Lancet Neurology.
[53] Eui Tae Kim,et al. SAMHD1 Restricts Herpes Simplex Virus 1 in Macrophages by Limiting DNA Replication , 2013, Journal of Virology.
[54] Baek Kim,et al. Host Factor SAMHD1 Restricts DNA Viruses in Non-Dividing Myeloid Cells , 2013, PLoS pathogens.
[55] Y. Guan,et al. Tropism of and Innate Immune Responses to the Novel Human Betacoronavirus Lineage C Virus in Human Ex Vivo Respiratory Organ Cultures , 2013, Journal of Virology.
[56] Zhijian J. Chen,et al. Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway , 2013, Science.
[57] John H Livingston,et al. Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature , 2012, Nature Genetics.
[58] Baek Kim,et al. The Vpx Lentiviral Accessory Protein Targets SAMHD1 for Degradation in the Nucleus , 2012, Journal of Virology.
[59] R. Naumann,et al. Mammalian RNase H2 removes ribonucleotides from DNA to maintain genome integrity , 2012, The Journal of experimental medicine.
[60] Baek Kim,et al. Tight Interplay among SAMHD1 Protein Level, Cellular dNTP Levels, and HIV-1 Proviral DNA Synthesis Kinetics in Human Primary Monocyte-derived Macrophages* , 2012, The Journal of Biological Chemistry.
[61] Baek Kim,et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates , 2012, Nature Immunology.
[62] B. Sobhian,et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx , 2011, Nature.
[63] Lina Sun,et al. The location of endogenous wild-type p53 protein in 293T and HEK293 cells expressing low-risk HPV-6E6 fusion protein with GFP. , 2010, Acta biochimica et biophysica Sinica.
[64] T. Wurdinger,et al. Real-Time Monitoring of Nuclear Factor κB Activity in Cultured Cells and in Animal Models , 2009, Molecular imaging.
[65] W. Miller,et al. Retinoids inhibit measles virus through a type I IFN‐dependent bystander effect , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[66] Jonathan C. Fuller,et al. Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune response , 2009, Nature Genetics.
[67] L. Ye,et al. Inhibition of hepatitis C virus infection by interferon-gamma through downregulating claudin-1. , 2009, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[68] Cun-Yu Wang,et al. MAVS Self-Association Mediates Antiviral Innate Immune Signaling , 2009, Journal of Virology.
[69] Thomas D. Schmittgen,et al. Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.
[70] A. Green,et al. Clinical and molecular phenotype of Aicardi-Goutieres syndrome. , 2007, American journal of human genetics.
[71] M. Desforges,et al. Activation of human monocytes after infection by human coronavirus 229E , 2007, Virus Research.
[72] C. Ponting,et al. Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutières syndrome and mimic congenital viral brain infection , 2006, Nature Genetics.
[73] D. Barnes,et al. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 cause Aicardi-Goutières syndrome at the AGS1 locus , 2006, Nature Genetics.
[74] Y. Lau,et al. Chemokine up-regulation in SARS-coronavirus–infected, monocyte-derived human dendritic cells , 2005, Blood.
[75] Y. Guan,et al. Cytokine Responses in Severe Acute Respiratory Syndrome Coronavirus-Infected Macrophages In Vitro: Possible Relevance to Pathogenesis , 2005, Journal of Virology.
[76] C. Der,et al. GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors , 2005, Nature Reviews Molecular Cell Biology.
[77] I. Krägeloh-Mann,et al. Cerebrospinal fluid pterins and folates in Aicardi-Goutières syndrome , 2003, Neurology.
[78] K. Kinzler,et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. , 1998, Science.
[79] J. Aicardi,et al. A Progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis , 1984, Annals of neurology.
[80] A. Heredia,et al. Interferon-gamma-induced downregulation of CD4 inhibits the entry of human immunodeficiency virus type-1 in primary monocytes. , 1995, Pathobiology : journal of immunopathology, molecular and cellular biology.